HopeStage
Back to all studies
TerminatedNCT01712646

Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

Medication studyAges 10–99United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 10 years to 99 years.

Listed locations
BethesdaSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateOctober 5, 2012
Recruitment status
Terminated
Enrollment listed in the registry
18
Sponsor
National Institute of Mental Health (NIMH)
Sponsor type
Government agency
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 10 Years to 99 Years
Official registry ID
NCT01712646
Official title
Show the full official title

The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial

Recruitment & locations

Terminated

Bethesda

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is National Institute of Mental Health (NIMH), a government agency.

Does this study involve medication?

Yes. The study involves medication, including Intranasal Oxytocin.

Who can participate?

Listed age limits: 10 years to 99 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies